Prolonged Survival in Metastatic Canine Cancer Using Immunovative Therapies’ CRCL Vaccine

13 Jul

Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies, describes a case in which a 12-year-old Great Dane presenting with primary bronchoalveolar adenocarcinoma, with a life expectancy no greater than 1 month, survived over 50 weeks post-diagnosis after being treated with Immunovative Therapies’ unique chaperone-rich-cell-lysate (CRCL) vaccine.

 

Prior to treatment by Immunovative Therapies, the Great Dane presented with ataxia, nystagmus, and hind-end collapse. Chest X-rays showed a nodule in the cranial lobe of the right lung. An ultrasound-guided fine needle biopsy showed bronchoalveolar adenocarcinoma, and the dog underwent thoracotomy and lobectomy. The specimen’s pathology report showed grade III bronchoalveolar adenocarcinoma with lymph node metastasis and vascular infiltration. The average survival for this tumor is 6 – 27 days.

 

Using Immunovative Therapies’ proprietary technology, a 10-gram piece of tumor was incorporated into a CRCL vaccine, which was administered weekly to the Great Dane. Additionally, Imiquimod – a Toll-like receptor 7 (TLR7) agonist – was topically administered to the dog for the first 12 treatments to stimulate local Langerhans cells. Furthermore, a single Bacillus Calmette-Guerin (BCG) shot was given at 30 weeks of treatment to further stimulate the dog’s immune response.

 

The Great Dane remained stable and in otherwise good health until it relapsed 44 weeks after the first treatment with Immunovative Therapies’ CRCL vaccine. The dog then suffered severe gastrointestinal bleeding and was euthanized just after 50 weeks post diagnosis.

 

Dr. Michael Har-Noy says that to his knowledge, this is the first report of significantly improved survival following a diagnosis of grade III/stage III bronchoalveolar adenocarcinoma in a canine patient. This case suggests that Immunovative Therapies’ CRCL vaccine combined with topical imiquimod is a safe and very effective treatment for canine cancer.

 

Immunovative Therapies Ltd. is a biotech company founded in Israel in 2004 by Dr. Michael Har-Noy. Immunovative Therapies manufactures unique compounds that focus on manipulating the immune system to fight cancer.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: